These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 23845174

  • 1. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
    Wiegand G, May TW, Ostertag P, Boor R, Stephani U, Franz DN.
    Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
    [Abstract] [Full Text] [Related]

  • 2. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.
    Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN.
    Ann Neurol; 2013 Nov; 74(5):679-87. PubMed ID: 23798472
    [Abstract] [Full Text] [Related]

  • 3. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczyński D, Kmieć T, Łojszczyk B, Dunin-Wąsowicz D, Jóźwiak S.
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [Abstract] [Full Text] [Related]

  • 4. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA.
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
    Moavero R, Mühlebner A, Luinenburg MJ, Craiu D, Aronica E, Curatolo P.
    Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
    [Abstract] [Full Text] [Related]

  • 13. [The Efficacy of Everolimus for Refractory Seizures in Childhood Onset Epilepsy with Tuberous Sclerosis Complex].
    Okanishi T, Fujimoto A, Nishimura M, Baba S, Itamura S, Okanari K, Enoki H.
    Brain Nerve; 2019 Jun; 71(6):611-616. PubMed ID: 31171758
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J, Dachowska I, Kotulska K, Baranska D, Fendler W, Jozwiak S, Mlynarski W.
    Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy and safety of rapamycin in treatment of children with epilepsy complicated with tuberous sclerosis].
    Zou L, Liu Y, Pang L, Ju J, Shi Z, Zhang J, Chen X, Su X, Hu L, Shi X, Yang X.
    Zhonghua Er Ke Za Zhi; 2014 Nov; 52(11):812-6. PubMed ID: 25582464
    [Abstract] [Full Text] [Related]

  • 17. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
    Moavero R, Coniglio A, Garaci F, Curatolo P.
    Ital J Pediatr; 2013 Sep 17; 39():57. PubMed ID: 24044547
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term treatment of epilepsy with everolimus in tuberous sclerosis.
    Krueger DA, Wilfong AA, Mays M, Talley CM, Agricola K, Tudor C, Capal J, Holland-Bouley K, Franz DN.
    Neurology; 2016 Dec 06; 87(23):2408-2415. PubMed ID: 27815402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.